Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 8:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 1,356 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Gene Expression Clear all
Terminated Phase 2 Interventional Results available

A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma

NCT03947255
View directory record Official record
Conditions
Hodgkin Lymphoma, Peripheral T Cell Lymphoma, Anaplastic Large Cell Lymphoma
Interventions
brentuximab vedotin
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
19
States / cities
Anaheim, California • Lafayette, Colorado • Pembroke Pines, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2023 · Synced Oct 20, 2026, 8:43 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Assessing Visual Processing in High Anxiety

NCT04187326
View directory record Official record
Conditions
Anxiety
Interventions
Facial Microexpression Training
Behavioral
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years to 30 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Oct 20, 2026, 8:43 AM EDT
Recruiting Phase 1Phase 2 Interventional

Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)

NCT05480449
View directory record Official record
Conditions
B Cell Acute Lymphoblastic Leukemia (B-ALL), B Lineage Lymphoblastic Lymphoma
Interventions
Autologous Humanized CD19-Directed Chimeric Antigen Receptor T-Cells (huCART19)
Biological
Lead sponsor
Stephan Grupp MD PhD
Other
Eligibility
0 Years to 29 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 20, 2026, 8:43 AM EDT
Completed Phase 2 Interventional Results available

EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma

NCT00114738
View directory record Official record
Conditions
Lymphoma, Mantle Cell, Mantle Cell Lymphoma
Interventions
Rituximab (R), EPOCH, Bortezomib (B), Bortezomib, Bortezomib or observation
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 10, 2022 · Synced Oct 20, 2026, 8:43 AM EDT
Completed Phase 4 Interventional Results available

Apremilast for RAS

NCT03690544
View directory record Official record
Conditions
Recurrent Aphthous Stomatitis
Interventions
Apremilast 30mg
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 14, 2022 · Synced Oct 20, 2026, 8:43 AM EDT
Completed Phase 2Phase 3 Interventional Results available

CPT and Smoking Cessation

NCT01901848
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic, Smoking
Interventions
Cognitive Processing Therapy (CPT), Bupropion, nicotine replacement therapy (NRT), Integrated Care for Smoking Cessation (ICSC), smokefreeVET
Behavioral · Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Oct 20, 2026, 8:43 AM EDT
Recruiting Phase 1 Interventional

FAPI-74 PET/CT in Adults With Fibrosis

NCT06413355
View directory record Official record
Conditions
Fibrosis (Morphologic Abnormality)
Interventions
[F-18]-FAPI-74
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
21 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 20, 2026, 8:43 AM EDT
Terminated No phase listed Observational

Effect of Sorafenib or Regorafenib on P63 Expression and Keratinocyte Differentiation in Human Skin

NCT01466504
View directory record Official record
Conditions
Renal Cell Carcinoma, Hepatocellular Carcinoma, Colorectal Carcinoma
Interventions
skin punch biopsy
Procedure
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Lebanon, New Hampshire • White River Junction, Vermont
Source: ClinicalTrials.gov public record
Updated Apr 15, 2013 · Synced Oct 20, 2026, 8:43 AM EDT
Completed Phase 4 Interventional

Investigation of Lithium on Signal Transduction, Gene Expression and Brain Myo-Inositol Levels in Manic Patients

NCT00870311
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lithium Carbonate
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2004
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 27, 2009 · Synced Oct 20, 2026, 8:43 AM EDT
Completed Phase 1 Interventional

Neoadjuvant Chemotherapy Followed by Radiation Therapy and Gemcitabine/Sorafenib/Vorinostat in Pancreatic Cancer

NCT02349867
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Recurrent Pancreatic Carcinoma
Interventions
Gemcitabine, Sorafenib, Vorinostat, 3-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy, RosetteSep, DEPfff
Drug · Radiation · Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 19, 2022 · Synced Oct 20, 2026, 8:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Sulforaphane as an Antagonist to Human PXR-mediated Drug-drug Interactions

NCT00621309
View directory record Official record
Conditions
Adverse Drug Interactions
Interventions
Rifampicin, sulforaphane plus rifampicin, sulforaphane alone
Drug · Dietary Supplement
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 40 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 6, 2019 · Synced Oct 20, 2026, 8:43 AM EDT
Terminated Phase 2 Interventional Results available

Clofarabine and Daunorubicin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT00814164
View directory record Official record
Conditions
Leukemia
Interventions
clofarabine, daunorubicin hydrochloride, cytogenetic analysis, protein expression analysis, immunologic technique, pharmacological study
Drug · Genetic · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
60 Years to 120 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 17, 2016 · Synced Oct 20, 2026, 8:43 AM EDT
Completed No phase listed Observational

Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract

NCT04069299
View directory record Official record
Conditions
Neuroendocrine Carcinoma
Interventions
68Ga-DOTATATE, Positron Emission Tomography (PET) Scan
Drug · Diagnostic Test
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 20, 2026, 8:43 AM EDT
Completed Phase 1 Interventional

GDC-0449 in Treating Young Patients With Medulloblastoma That is Recurrent or Did Not Respond to Previous Treatment

NCT00822458
View directory record Official record
Conditions
Recurrent Childhood Medulloblastoma
Interventions
vismodegib, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
3 Years to 21 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
9
States / cities
San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2014 · Synced Oct 20, 2026, 8:43 AM EDT
Terminated Phase 1 Interventional

A Molecular Pharmacodynamic Dose-titration Trial of Conjugated Linoleic Acid (CLA; Clarinol®) in Patients With Advanced Solid Tumors

NCT00951158
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
Conjugated Linoleic Acid, Conjugated Linoleic Acid
Dietary Supplement · Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated May 12, 2015 · Synced Oct 20, 2026, 8:43 AM EDT
Enrolling by invitation Not applicable Interventional

Gene Expression in Lower Extremity Acute Traumatic Compartment Syndrome

NCT05521958
View directory record Official record
Conditions
Tibial Shaft Fracture, Tibial Plateau Fracture
Interventions
Acute injury without compartment syndrome, Acute injury with compartment syndrome, Exertional compartment syndrome
Procedure
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 90 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 20, 2026, 8:43 AM EDT
Completed No phase listed Observational

Effect of Atorvastatin (Lipitor) on Gene Expression in People With Vascular Disease

NCT00293748
View directory record Official record
Conditions
Vascular Disease, Vascular Disease Risk
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
21 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 20, 2026, 8:43 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Ethical, Legal, and Social Issues Substudy in Relation to the GTEx Project

NCT02887339
View directory record Official record
Conditions
Standard Training, Online Training
Interventions
Training Website, Control
Other
Lead sponsor
Temple University
Other
Eligibility
Not listed
Enrollment
512 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 30, 2021 · Synced Oct 20, 2026, 8:43 AM EDT
Withdrawn Phase 4 Interventional

Impact of Sirolimus and Maraviroc on CCR5 Expression and the HIV-1 Reservoir in HIV-infected Kidney Transplant Recipients

NCT02990312
View directory record Official record
Conditions
Hiv, Kidney Transplant, HIV Reservoir, CCR5
Interventions
Sirolimus + Maraviroc
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Oct 20, 2026, 8:43 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

The Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose Administration In Men With Prostate Cancer Undergoing Androgen Deprivation Therapy Compared to Normal Healthy Females

NCT03436745
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Zolpidem, ECG
Drug · Diagnostic Test
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 20, 2026, 8:43 AM EDT
Completed Phase 1 Interventional

Safety Study in Subjects With Leber Congenital Amaurosis

NCT00516477
View directory record Official record
Conditions
Leber Congenital Amaurosis
Interventions
voretigene neparvovec-rzyl
Biological
Lead sponsor
Spark Therapeutics, Inc.
Industry
Eligibility
8 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 2, 2020 · Synced Oct 20, 2026, 8:43 AM EDT
Completed Phase 4 Interventional

Pulse Reduction On Beta-blocker and Ivabradine Therapy

NCT02973594
View directory record Official record
Conditions
Dilated Cardiomyopathies, Idiopathic, Heart Failure, Systolic, Ventricular Remodeling, Electrical Remodeling
Interventions
Ivabradine, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
2
States / cities
Aurora, Colorado • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Oct 20, 2026, 8:43 AM EDT
Withdrawn Phase 2 Interventional

Diabetes Autoimmunity Withdrawn in New Onset Patients (DAWN)

NCT03794973
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
TOL-3021, TOL-3021 Placebo
Biological · Other
Lead sponsor
Tolerion, Inc.
Industry
Eligibility
12 Years to 35 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Oct 20, 2026, 8:43 AM EDT
Withdrawn Not applicable Interventional

Prenatal Breastfeeding Education

NCT04549129
View directory record Official record
Conditions
Breast Feeding
Interventions
Breastfeeding education video, Breastfeeding website, Usual breastfeed education
Behavioral
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Quincy, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Oct 20, 2026, 8:43 AM EDT